Boston Scientific (BSX) closed at $44.51 in the latest trading session, marking a -2.35% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 1.05%.
Shares of the medical device manufacturer witnessed a gain of 1.47% over the previous month, trailing the performance of the Medical sector with its gain of 3.5%, and outperforming the S&P 500's gain of 0.97%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on October 28, 2026. On that day, Boston Scientific is projected to report earnings of $0.76 per share, which would represent year-over-year growth of 1.33%. Our most recent consensus estimate is calling for quarterly revenue of $5.17 billion, up 2.12% from the year-ago period.
BSX's full-year Zacks Consensus Estimates are calling for earnings of $3.24 per share and revenue of $21.17 billion. These results would represent year-over-year changes of +5.88% and +5.45%, respectively.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.89% lower. Boston Scientific currently has a Zacks Rank of #4 (Sell).
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 14.08. This represents a discount compared to its industry average Forward P/E of 20.56.
Meanwhile, BSX's PEG ratio is currently 1.1. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Medical - Products industry was having an average PEG ratio of 1.88.
The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 158, finds itself in the bottom 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).